Estrella Immunopharma, Inc. SEC filings ESLAW
Estrella Immunopharma, Inc. has 258 filings in SEC EDGAR's recent list, going back to Feb 19, 2021. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 29, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 8, 2026 | Sep 1, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Listing notice
|
Jan 13, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jan 6, 2026 | Jan 5, 2026 |
| 8-K |
Current report
Other events
|
Dec 4, 2025 | Dec 4, 2025 |
| 8-K |
Current report
Other events
|
Nov 6, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Other events
|
Sep 29, 2025 | Sep 23, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 26, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 7, 2025 | Aug 1, 2025 |
| 8-K |
Current report
Other events
|
Jun 5, 2025 | Jun 5, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 3, 2025 | May 30, 2025 |
| 8-K |
Current report
Other events
|
May 29, 2025 | May 29, 2025 |
| 8-K |
Current report
Listing notice
|
May 2, 2025 | Apr 30, 2025 |
| 8-K |
Current report
Other events
|
Feb 21, 2025 | Feb 21, 2025 |
| 8-K |
Current report
Other events
|
Feb 20, 2025 | Feb 19, 2025 |
| 8-K |
Current report
Other events
|
Dec 16, 2024 | Dec 16, 2024 |
| 8-K |
Current report
Material agreement
|
Dec 6, 2024 | Dec 4, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 26, 2024 | Nov 25, 2024 |
| 8-K |
Current report
Listing notice
|
Nov 25, 2024 | Nov 25, 2024 |
| 8-K/A |
Amended current report
Material agreement, Officer or director change
|
Nov 7, 2024 | Aug 14, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 7, 2024 | Nov 1, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 20, 2024 | Aug 14, 2024 |
| 8-K |
Current report
Other events
|
Aug 6, 2024 | Jul 31, 2024 |
| 8-K |
Current report
Other events
|
Jul 2, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Material agreement
|
May 13, 2024 | May 13, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 10, 2024 | Apr 10, 2024 |
| 8-K |
Current report
Other events
|
Mar 11, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Material agreement
|
Mar 7, 2024 | Mar 4, 2024 |
| 8-K |
Current report
Auditor change
|
Feb 2, 2024 | Jan 30, 2024 |
| 8-K |
Current report
Other events
|
Jan 30, 2024 | Jan 30, 2024 |
| 8-K/A |
Amended current report
Bylaw or fiscal year change
|
Nov 14, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Listing notice, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change
|
Oct 5, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 20, 2023 | Sep 14, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 18, 2023 | Sep 18, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Aug 18, 2023 | Aug 18, 2023 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Aug 1, 2023 | Jul 31, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jul 26, 2023 | Jul 25, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 21, 2023 | Jul 20, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Jul 19, 2023 | Jul 18, 2023 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jul 19, 2023 | Jul 17, 2023 |
| 8-K |
Current report
Other events
|
Jul 12, 2023 | Jul 11, 2023 |
| 8-K |
Current report
Listing notice
|
Jun 23, 2023 | Jun 22, 2023 |
| 8-K |
Current report
Material agreement
|
Jun 20, 2023 | Jun 16, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jun 9, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
May 19, 2023 | May 19, 2023 |
| 8-K |
Current report
Material agreement
|
Apr 26, 2023 | Apr 26, 2023 |
| 8-K |
Current report
Material agreement
|
Apr 24, 2023 | Apr 20, 2023 |
| 8-K |
Current report
Listing notice
|
Apr 21, 2023 | Apr 19, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Apr 13, 2023 | Apr 12, 2023 |
| 8-K |
Current report
Listing notice
|
Apr 5, 2023 | Apr 3, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Mar 20, 2023 | Mar 17, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Mar 3, 2023 | Mar 3, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Feb 21, 2023 | Feb 17, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Jan 24, 2023 | Jan 19, 2023 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change, Other events
|
Jan 5, 2023 | Dec 29, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Dec 29, 2022 | Dec 22, 2022 |
| 8-K |
Current report
Auditor change
|
Oct 11, 2022 | Oct 10, 2022 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 3, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Jul 27, 2022 | Jul 25, 2022 |
| 8-K |
Current report
Other events
|
Sep 3, 2021 | Sep 3, 2021 |
| 8-K |
Current report
Other events
|
Jul 22, 2021 | Jul 19, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Jul 19, 2021 | Jul 14, 2021 |
Showing 64 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ESLA (Nasdaq), ESLAW (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1844417
- Former names
- TradeUP Acquisition Corp. (until Sep 20, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.